Lonza LONN -1.32%decrease; down pointing triangle Group said it expects maturing growth projects and cost discipline to boost profitability over the medium term, as the group reiterated its full-year outlook.

The Swiss company on Wednesday laid out its midterm growth targets that reflect its transformation into a group purely focused on the contract drug-manufacturing business following the planned sale of its capsules-and-health-ingredients unit to Lone Star Funds.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8